Skip to main content

Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder Arthroplasty

Active, not recruiting · Not applicable · NCT03726554

Conditions: Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects, Post-Traumatic Arthritis

At a glance

Research payments reported, 2025
$37,870
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
99

About the trial

Sponsor
Zimmer Biomet
Tested
Comprehensive Reverse Porous Augmented Glenoid (device), Comprehensive Mini Humeral Tray (device)
Dates
Started 2018-08-28; completion 2030-02
Results posted
Not yet

This study is a multicenter, prospective, non-randomized, non-controlled, dual cohort post market surveillance study. The primary objective of this study is to confirm the safety and performance of the Comprehensive Reverse Shoulder System when used with the Comprehensive Porous Augmented Glenoid Baseplate and/or Comprehensive Mini Humeral Tray in primary and revision reverse shoulder arthroplasty.

From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Zimmer Biomet Holdings, Inc. reported $37,870 in research payments for this study in 2025 (5 payments).

Products named: Comprehensive Shoulder System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Norton Healthcare Childrens Hospital Foundation $24,657
  • Andrews Research & Education Foundation $13,213

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.